These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy]. MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111 [No Abstract] [Full Text] [Related]
6. Potassium channels, memory T cells, and multiple sclerosis. Beeton C; Chandy KG Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596 [TBL] [Abstract][Full Text] [Related]
7. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Sun J; Lin Z; Feng J; Li Y; Shen B Eur J Pharmacol; 2008 Nov; 597(1-3):1-5. PubMed ID: 18793632 [TBL] [Abstract][Full Text] [Related]
8. Aspects of cellular immunity in autoimmune thrombocytopenic purpura. Kaufman S; Peller S; Sigler E Isr J Med Sci; 1983 Mar; 19(3):271-3. PubMed ID: 6602117 [No Abstract] [Full Text] [Related]
9. Autoimmune diseases. The B cell slayer. Matthews R Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858 [No Abstract] [Full Text] [Related]
10. Bedside to bench: betting on B cells in multiple sclerosis. Link H Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578 [No Abstract] [Full Text] [Related]
11. Copolymer 1 from the laboratory to FDA. Teitelbaum D; Sela M; Arnon R Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880 [No Abstract] [Full Text] [Related]
12. [Clinico-immunologic parallels in evaluating the treatment of multiple sclerosis]. Chernigovskaia NV; Ogurtsov RP; Matveeva TS; Popov VG; Puzyreva VP Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(2):24-8. PubMed ID: 2160163 [TBL] [Abstract][Full Text] [Related]
13. B cell signalling as therapeutic target. Carter RH Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii65-ii66. PubMed ID: 15479875 [No Abstract] [Full Text] [Related]
14. Epstein-Barr virus in the development of multiple sclerosis. Ascherio A Expert Rev Neurother; 2008 Mar; 8(3):331-3. PubMed ID: 18345964 [No Abstract] [Full Text] [Related]
15. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799 [TBL] [Abstract][Full Text] [Related]
16. [Clinico-immunologic correlations in disseminated sclerosis]. Zavalishin IA; Khondkarian OA; Nevskaia OM; Pivovarova AI Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(2):164-7. PubMed ID: 6608842 [TBL] [Abstract][Full Text] [Related]
17. Immunoregulation of autoimmunity by natural killer T cells. Linsen L; Somers V; Stinissen P Hum Immunol; 2005 Dec; 66(12):1193-202. PubMed ID: 16690406 [TBL] [Abstract][Full Text] [Related]
18. [Comparative analysis of the use of levamisole and pyrogenal in the treatment of multiple sclerosis]. Mukhtarova AA Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):366-7. PubMed ID: 3873154 [TBL] [Abstract][Full Text] [Related]
19. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. Mokhtarian F; Shi Y; Shirazian D; Morgante L; Miller A; Grob D J Immunol; 1994 Jun; 152(12):6003-10. PubMed ID: 8207225 [TBL] [Abstract][Full Text] [Related]